BCIQ Profiles

Company Profile Report
0409 DiLenge departing
BioCentury & Getty Images

Politics, Policy & Law

DiLenge predicts biopharma companies will ‘take a hit’ in infrastructure bill

BIO’s goal is to ensure that drug pricing legislation increases patient access, doesn’t harm innovation

BIO’s goal is to ensure that drug pricing legislation increases patient access without harming innovation.

Apr 10, 2021 | 12:23 AM GMT

As he prepares to leave BIO after 15 years, Tom DiLenge previewed the urgent policy challenges the industry will face in the coming months, including pending drug price control legislation that could reshape the U.S. market.

DiLenge, who has been BIO’s president for advocacy, law & public policy for the past five years after serving as

Read the full 1095 word article

How to gain access

Continue reading with a
two-week free trial.